.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its own best biopharma pick for 2025 as well as ranked another nine titles in the space as over weight. The assets financial institution pointed out in a note that it remains to feel “diabesity is actually set to come to be.